Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947007 | 1.00 | LGALS8 (0.53) | LGALS8SLC6A2SLC5A2SLC5A1SSTR5 | |
| SCHEMBL7152720 | 0.93 | LGALS8 (0.60) | LGALS8SLC6A2SSTR5SSTR1SSTR2 | |
| SCHEMBL21706804 | 0.93 | LGALS8 (0.60) | LGALS8SLC6A2SSTR5SSTR1SSTR2 | |
| SCHEMBL7152294 | 0.93 | LGALS8 (0.60) | LGALS8SLC6A2SSTR5SSTR1SSTR2 | |
| SCHEMBL3156075 | 0.93 | LGALS8 (0.60) | LGALS8SLC6A2SSTR5SSTR1SSTR2 | |
| SCHEMBL6951099 | 0.90 | SSTR5 (0.54) | LGALS8SSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL7150592 | 0.89 | LGALS8 (0.58) | LGALS8SLC6A2SLC5A2SSTR5SSTR1 | |
| SCHEMBL3152068 | 0.89 | LGALS8 (0.58) | LGALS8SLC6A2SSTR5SSTR1SSTR2 | |
| SCHEMBL3660543 | 0.88 | SLC6A2 (0.48) | LGALS8SLC6A2SLC5A2SLC5A1SSTR5 | |
| SCHEMBL15481400 | 0.86 | SLC6A2 (0.57) | LGALS8SLC6A2SLC5A2SLC5A1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | LGALS8 198/4885SLC6A2 2866/4885SLC5A2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.